Patient perspectives on incretin‐based weight loss medications and relationship with demographic factors
Abstract Objective Treatment of obesity has been transformed by the recent approval of incretin‐based therapies for weight loss (e.g., glucagon‐like peptide 1 agonist semaglutide), but little is known about patient perspectives on these medications. Methods Between December 2023 and March 2024, heal...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-08-01
|
| Series: | Obesity Science & Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/osp4.783 |